ChiCTR-OPQ-14005299: Tolerance, pharmacokinetics and pharmacodynamics of PEG-INF-alpha 2b in healthly volunteers: A Randomized, Single center, drug control, Open-Label study |
|
|
| Recruiting | 1 | 58 | | PegIntron subcutaneously ;PEGASYS subcutaneously ;hypodermic | West China Hospital, Sichuan University; West China Hospital, Sichuan University, ANHUI ANKE BIO TECNOLOGY(GROUP) CO.,LTD | Chronic hepatitis B and C | | | | |
BEAT-2, NCT03588715: Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 |
|
|
| Active, not recruiting | 1 | 15 | US | Pegylated Interferon alpha 2b (peg-IFN-α2b), Pegintron, 3BNC117 + 10-1074, Broadly Neutralizing Antibodies | Luis Montaner, University of Pennsylvania, Philadelphia Fight, Rockefeller University, Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID) | HIV, HIV/AIDS, HIV-1 Infection | 12/21 | 10/22 | | |
